TW200728276A - Oxindole derivatives - Google Patents

Oxindole derivatives

Info

Publication number
TW200728276A
TW200728276A TW095122208A TW95122208A TW200728276A TW 200728276 A TW200728276 A TW 200728276A TW 095122208 A TW095122208 A TW 095122208A TW 95122208 A TW95122208 A TW 95122208A TW 200728276 A TW200728276 A TW 200728276A
Authority
TW
Taiwan
Prior art keywords
compounds
oxindole derivatives
cancer
manufacture
general formula
Prior art date
Application number
TW095122208A
Other languages
English (en)
Inventor
Kin-Chun Luk
Sung-Sau So
Jing Zhang
zhu-ming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200728276A publication Critical patent/TW200728276A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
TW095122208A 2005-06-24 2006-06-21 Oxindole derivatives TW200728276A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69375205P 2005-06-24 2005-06-24
US79561606P 2006-04-27 2006-04-27

Publications (1)

Publication Number Publication Date
TW200728276A true TW200728276A (en) 2007-08-01

Family

ID=37114613

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095122208A TW200728276A (en) 2005-06-24 2006-06-21 Oxindole derivatives

Country Status (16)

Country Link
US (1) US7576082B2 (zh)
EP (1) EP1896412A2 (zh)
JP (1) JP2008543917A (zh)
KR (1) KR100990344B1 (zh)
CN (1) CN101203489B (zh)
AR (1) AR054799A1 (zh)
AU (1) AU2006260934B2 (zh)
BR (1) BRPI0612535A2 (zh)
CA (1) CA2612451A1 (zh)
DO (1) DOP2006000141A (zh)
IL (1) IL188039A0 (zh)
MX (1) MX2007016038A (zh)
PA (1) PA8680701A1 (zh)
TW (1) TW200728276A (zh)
UY (1) UY29633A1 (zh)
WO (1) WO2006136606A2 (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034736A2 (en) * 2006-09-21 2008-03-27 F. Hoffmann-La Roche Ag Oxindole derivatives as anticancer agents
PE20081897A1 (es) 2007-03-29 2009-02-09 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
WO2009011872A1 (en) 2007-07-17 2009-01-22 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
WO2011060049A2 (en) * 2009-11-12 2011-05-19 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CN103298818B (zh) 2010-11-12 2016-06-29 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
CN103380125B (zh) 2010-12-21 2015-11-25 拜耳知识产权有限责任公司 制备三嗪基取代的羟吲哚的方法
CN103502218B (zh) 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
SG10201601802YA (en) 2011-03-10 2016-04-28 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivatives
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
JP6373978B2 (ja) 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
WO2014191906A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
CA2931249A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
US9718775B2 (en) 2014-03-14 2017-08-01 Milliken & Company Oxindole compounds and compositions comprising the same
CN107427501B (zh) 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Mdm2阻害剤とbtk阻害剤との併用治療法
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
UA123786C2 (uk) 2016-04-06 2021-06-02 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка mdm2
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
TW201818934A (zh) 2016-10-17 2018-06-01 日商第一三共股份有限公司 Mdm2抑制劑與dna甲基轉移酶抑制劑之倂用治療法
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
CN108610277A (zh) * 2018-03-20 2018-10-02 贵州大学 3-叔胺四取代氧化吲哚化合物及其制备方法
JP2022504541A (ja) 2018-10-08 2022-01-13 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 低分子mdm2タンパク質デグレーダー
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN113880750B (zh) * 2021-10-28 2023-02-10 上海交通大学 一种手性3-取代-3-芳基氧化吲哚类化合物的合成方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759935A (en) 1953-02-18 1956-08-21 Bristol Lab Inc Substituted 3-phenyloxindoles
US3441570A (en) 1966-01-20 1969-04-29 Parke Davis & Co 3-tertiary aminoalkylamino-3-phenyl oxindole compounds
US3686210A (en) 1970-01-13 1972-08-22 American Home Prod 2-acylamido-3-aryl-3h-indol-3-ol esters and related compounds
GB1494340A (en) * 1974-12-03 1977-12-07 Wyeth John & Brother Ltd Process for preparation of substituted n-phenylcarbamate esters
US4020179A (en) 1975-05-15 1977-04-26 Richardson-Merrell Inc. 7-Substituted-2-indolinones
JPS55129284A (en) 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
JP3748935B2 (ja) * 1996-03-18 2006-02-22 大鵬薬品工業株式会社 オキシインドール誘導体
AU3460797A (en) 1996-07-16 1998-02-09 Takeda Chemical Industries Ltd. Bicyclic compounds for controlling micturition
WO1998054167A1 (fr) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'indole
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
JP2000191661A (ja) 1998-12-25 2000-07-11 Mitsubishi-Tokyo Pharmaceuticals Inc 環状アミド化合物
EP1183033B1 (en) 1999-05-21 2006-03-01 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US8030499B2 (en) 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle

Also Published As

Publication number Publication date
KR100990344B1 (ko) 2010-10-29
WO2006136606A3 (en) 2007-04-26
EP1896412A2 (en) 2008-03-12
CA2612451A1 (en) 2006-12-28
US20060293319A1 (en) 2006-12-28
AR054799A1 (es) 2007-07-18
KR20080022117A (ko) 2008-03-10
BRPI0612535A2 (pt) 2010-11-23
AU2006260934B2 (en) 2012-03-29
WO2006136606A2 (en) 2006-12-28
IL188039A0 (en) 2008-03-20
MX2007016038A (es) 2008-03-10
PA8680701A1 (es) 2007-01-17
DOP2006000141A (es) 2006-12-31
UY29633A1 (es) 2007-01-31
CN101203489B (zh) 2011-08-31
US7576082B2 (en) 2009-08-18
JP2008543917A (ja) 2008-12-04
AU2006260934A1 (en) 2006-12-28
CN101203489A (zh) 2008-06-18

Similar Documents

Publication Publication Date Title
TW200728276A (en) Oxindole derivatives
TW200637828A (en) Novel cis-imidazolines
GEP20105024B (en) Fused heterocyclic compound
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
TW200726748A (en) Chemical compounds II
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200639156A (en) New compounds
GB0710121D0 (en) Antifungal agents
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
TW200736236A (en) Process for the manufacturing of pharmaceutically active compounds
IL206397A (en) Cytotoxic substances, preparations containing these substances and their use in the treatment of tumors
TW200716618A (en) Chemical compounds
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents